DDInter1328 DDInter875
Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and blocks ligand binding. It is composed of two heavy chain molecule fragments and 2 light chain fragments. Studies show that the treatment of olaratumab in combination with doxorubicin resulted in significant reduction of cancer cell proliferation and tumor growth. Olaratumab was granted accelerated approval (as Lartruvo) as initial therapy to treat adults with certain types of soft tissue sarcoma (STS) in October, 2016.
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Olaratumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Olaratumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anakinra
Olaratumab {u} may lead to a major life threatening interaction when taken with {v} Measles virus vaccine live attenuated
Olaratumab {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Olaratumab may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Olaratumab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra
Olaratumab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Olaratumab may lead to a major life threatening interaction when taken with Leflunomide